Filing Details

Accession Number:
0001593968-21-002569
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-22 18:54:16
Reporting Period:
2021-12-20
Accepted Time:
2021-12-22 18:54:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
887359 Vericel Corp VCEL Biological Products, (No Disgnostic Substances) (2836) 943096597
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1626325 Mark Jonathan Hopper C/O Vericel Corporation
64 Sidney Street
Cambridge MA 02139
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-20 1,000 $10.95 40,428 No 4 M Direct
Common Stock Disposition 2021-12-20 1,000 $40.00 39,428 No 4 S Direct
Common Stock Acquisiton 2021-12-22 9,000 $10.95 48,428 No 4 M Direct
Common Stock Disposition 2021-12-22 9,000 $40.14 39,428 No 4 S Direct
Common Stock Acquisiton 2021-12-22 10,000 $16.66 49,428 No 4 M Direct
Common Stock Disposition 2021-12-22 5,881 $40.08 43,547 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-12-20 1,000 $0.00 1,000 $10.95
Common Stock Stock Option (right to buy) Disposition 2021-12-22 9,000 $0.00 9,000 $10.95
Common Stock Stock Option (right to buy) Disposition 2021-12-22 10,000 $0.00 10,000 $16.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
56,604 2028-08-20 No 4 M Direct
47,604 2028-08-20 No 4 M Direct
16,000 2029-02-06 No 4 M Direct
Footnotes
  1. These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
  2. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021.
  3. These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.
  4. These options, representing the right to purchase a total of 26,000 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 6, 2019.